Agenus Inc.

AGEN Healthcare Biotechnology

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.

6.04 0.64 −9.58%
Market cap
$301.7M
P/E
2.3×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
−14.16
Beneish M
12.57
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

12.80% 0.03% (23.40%) (33.86%)
Piotroski F-Score
2 4 5 6
ROA
(14.98%) (0.04%) 33.31% 51.30%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
25.79% 0.06% (46.32%) (66.19%)
Average Days of Receivables
21.40 22.41 159.31 151.84
Free Cash Flow per Share
(2.79) (2.58) (2.30) (2.37)
Free Cash Flow
(88.95) (76.84) (87.14) (98.16)
Capital Expenditures
0.28 0.35 0.39 0.35
Other line items
Cash ROIC
36.57% 33.38% 53.53% 62.50%
Accounts Receivable Turnover
33.02 30.79 4.55 4.75
Accounts Payable Turnover
0.02 0.01 0.00 0.00
Inventory Turnover
0.00 0.00 — —
Average Days of Payables
27,307.44 29,638.21 0.00 0.00
Days of Inventory on Hand
0.00 0.00 — —
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
98.85% 69.48% 56.22% 43.47%
Selling, General and Administrative Expense of Revenue
59.00% 47.63% 36.76% 29.00%
Share Based Compensation of Revenue
14.03% 12.06% 9.19% 8.60%
Interest Coverage
(1.01) (0.36) 0.14 0.61
Operating CF/Net income
2.52 764.31 (1.36) (1.07)
Depreciation/Fixed assets
0.79 0.65 0.49 0.33
Capex/Depreciation
0.02 0.04 0.05 0.07
Revenue per Share
3.35 3.84 3.26 3.21
Operating CF per Share
(2.80) (2.60) (2.31) (2.38)
Capex per Share
0.01 0.01 0.01 0.01
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates